Patients and methods
toxicity
DISEASE
This trial is a Phase I/II dose escalation approved by the Ethics Committee of Canton Vaud (ClinicalTrials.gov ID: NCT02254746). All patients provided written informed consent. Eligible patients, enrolled between October 2014 and April 2017, were those with newly diagnosed and previously untreated PCa, low, intermediate- and high-risk disease according to the D'Amico risk classification,The primary endpoint of the study was to assess acute (up to 90 days after the first RT fraction) urinary and rectal toxicity. Secondary endpoints were biochemical control, quality of life (QofL), and dosimetry outcomes.